Our portfolio
We are the largest buyer of biopharmaceutical royalties and the partner of choice for biopharma funding solutions. This gives us access to a rich pipeline of opportunities and has helped us to build an enviable portfolio of market-leading therapies.
Rytelo
Lower-risk myelodysplastic syndromes
- Geron (Marketer)
- Geron (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2024 | Approved |
Niktimvo
Chronic graft-versus-host disease (GVHD)
- Syndax Pharmaceuticals (Marketer)
- Incyte Corporation (Marketer)
- Syndax Pharmaceuticals (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2024 | Approved |
Yorvipath
hypoparathyroidism
- Ascendis Pharma (Marketer)
- Ascendis Pharma (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2024 | Approved |
Voranigo
Low-grade glioma
- Servier (Marketer)
- Agios Pharmaceuticals (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2024 | Approved |
Evrysdi
Spinal muscular atrophy
- Roche (Marketer)
- PTC Therapeutics (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2023 | Approved |
| 2020 | Pre-Approval |
Skytrofa
Growth hormone deficiency
- Ascendis Pharma (Marketer)
- Ascendis Pharma (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2023 | Approved |
Adstiladrin
Bladder cancer
- Ferring Pharmaceuticals (Marketer)
- Ferring Pharmaceuticals (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2023 | Approved |
Cobenfy
Schizophrenia
- Bristol Myers Squibb (Marketer)
- PureTech Health (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2023 | Pre-Approval |
Spinraza
Spinal muscular atrophy
- Biogen (Marketer)
- Ionis Pharmaceuticals (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2023 | Approved |
Trelegy Ellipta
Chronic obstructive pulmonary disease, asthma
- GSK (Marketer)
- Theravance Biopharma (Seller)
- Innoviva (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2022 | Approved |
Orladeyo
Hereditary angioedema
- BioCryst Pharmaceuticals (Marketer)
- BioCryst Pharmaceuticals (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2021 | Approved |
| 2020 | Approved |
Tremfya
Plaque psoriasis, active psoriatic arthritis, ulcerative colitis
- Johnson & Johnson (Marketer)
- MorphoSys (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2021 | Approved |
Oxlumo
Primary hyperoxaluria type 1
- Alnylam Pharmaceuticals (Marketer)
- Dicerna Pharmaceuticals (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2021 | Approved |
Cabometyx/Cometriq
Kidney, liver and thyroid cancer
- Exelixis (Marketer)
- Ipsen (Marketer)
- Takeda Pharmaceuticals (Marketer)
- GSK (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2021 | Approved |
Kalydeco
Cystic fibrosis
- Vertex Pharmaceuticals (Marketer)
- Cystic Fibrosis Foundation (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2020 | Approved |
| 2014 | Approved |
Orkambi
Cystic fibrosis
- Vertex Pharmaceuticals (Marketer)
- Cystic Fibrosis Foundation (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2020 | Approved |
| 2014 | Approved |
Symdeko
Cystic fibrosis
- Vertex Pharmaceuticals (Marketer)
- Cystic Fibrosis Foundation (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2020 | Approved |
| 2014 | Pre-Approval |
Trikafta
Cystic fibrosis
- Vertex Pharmaceuticals (Marketer)
- Cystic Fibrosis Foundation (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2020 | Approved |
| 2014 | Pre-Approval |
Nurtec ODT
Migraine
- Pfizer (Marketer)
- Biohaven (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2020 | Approved |
| 2018 | Pre-Approval |
Zavzpret
Migraine
- Pfizer (Marketer)
- Biohaven (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2020 | Pre-Approval |
| 2018 | Pre-Approval |
IDHIFA
Blood cancer
- Bristol Myers Squibb (Marketer)
- Agios Pharmaceuticals (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2020 | Approved |
Prevymis
Cytomegalovirus infection
- Merck (Marketer)
- AiCuris (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2020 | Approved |
Entyvio
Ulcerative colitis, Crohn's disease
- Takeda Pharmaceuticals (Marketer)
- Massachusetts General Hospital (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2020 | Approved |
Tazverik
Epithelioid sarcoma, follicular lymphoma
- Ipsen (Marketer)
- Eisai (Seller)
- Epizyme, Inc. (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2019 | Pre-Approval |
Crysvita
X-linked hypophosphatemia
- Kyowa Kirin (Marketer)
- Ultragenyx (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2019 | Approved |
Erleada
Prostate cancer
- Johnson & Johnson (Marketer)
- University of California (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2023 | Approved |
| 2019 | Approved |
Emgality
Migraine
- Lilly (Marketer)
- Arteaus Therapeutics (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2019 | Approved |
Promacta
Chronic immune thrombocytopenia
- Novartis (Marketer)
- Ligand (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2019 | Approved |
Trodelvy
Breast cancer
- Gilead Sciences (Marketer)
- Immunomedics (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2018 | Pre-Approval |
Airsupra
Asthma
- AstraZeneca (Marketer)
- AstraZeneca (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2023 | Approved |
| 2018 | Pre-Approval |
Tysabri
Multiple sclerosis
- Biogen (Marketer)
- Perrigo (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2017 | Approved |
Xtandi
Prostate cancer
- Astellas Pharma (Marketer)
- Pfizer (Marketer)
- UCLA (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2016 | Approved |
Bosulif
Blood cancer
- Pfizer (Marketer)
- Pfizer (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2014 | Pre-Approval |
Soliqua
Diabetes
- Sanofi (Marketer)
- Zealand Pharma (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2012 | Pre-Approval |
imbruvica
Blood cancer
- AbbVie (Marketer)
- Johnson & Johnson (Marketer)
- Quest Diagnostics (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2013 | Pre-Approval |
Cimzia
Rheumatoid arthritis
- UCB (Marketer)
- Nektar Therapeutics (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2012 | Approved |
Mircera
Chronic kidney disease
- Roche (Marketer)
- Nektar Therapeutics (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2012 | Approved |
Januvia
Diabetes
- Merck (Marketer)
- Astellas Pharma (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2011 | Approved |
Onglyza
Diabetes
- AstraZeneca (Marketer)
- Astellas Pharma (Seller)
| Year of acquisition | Status at acquisition |
|---|---|
| 2011 | Approved |
Lexiscan
Pharmacological stress agent for myocardial perfusion imaging
- Astellas Pharma (Marketer)
| Year of acquisition | Status at acquisition |
|---|---|
| 2011 | Approved |
Letairis
Pulmonary arterial hypertension
- Gilead Sciences (Marketer)
| Year of acquisition | Status at acquisition |
|---|---|
| 2009 | Approved |
